SSY Group (02005.HK): Sodium Glycerophosphate Injection Obtains NMPA Drug Production Registration Approval

NewTimeSpace · 2025/12/30 16:23 · By Zeyu Wu

SSY Group Co., Ltd. (02005.HK) announced on December 29, 2025 that the Group has obtained the Drug Production Registration Approval for Sodium Glycerophosphate Injection (10ml:2.16g) from the National Medical Products Administration (NMPA) of China. As a Class 4 Chemical Drug, the product is deemed to have passed the Consistency Evaluation, making SSY Group the third domestic enterprise to receive such approv

In a voluntary announcement released on December 29, 2025, SSY Group Co., Ltd. (02005.HK) stated that the Group has been granted the Drug Production Registration Approval for Sodium Glycerophosphate Injection (10ml:2.16g) by China’s NMPA. Classified as a Class 4 Chemical Drug, the product is deemed to have passed the Consistency Evaluation, and SSY Group is the third domestic enterprise to obtain approval for this product.

Sodium Glycerophosphate Injection is a nutritional drug, mainly used as a phosphorus supplement for parenteral nutrition in adults and for patients with phosphorus deficiency.

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "新时空" or "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.

Tags：

SSY Group 02005.HK New Drug Update